| HER-2、p53的表达对乳腺癌蒽环类新辅助化疗疗效的影响 |
| |
| 引用本文： | 王晓兰,陈波,姚凡,李继光,刘楠,邱雪杉,刘彩刚,金锋.HER-2、p53的表达对乳腺癌蒽环类新辅助化疗疗效的影响[J].山东医药,2008,48(32):1-3. |
| |
| 作者姓名： | 王晓兰 陈波 姚凡 李继光 刘楠 邱雪杉 刘彩刚 金锋 |
| |
| 作者单位： | 中国医科大学附属第一医院,辽宁,沈阳110001 |
| |
| 摘 要： | 目的 研究乳腺癌雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体-2(c-erbB2)及p53的表达与以蒽环类为基础的新辅助化疗(NAC)疗效之间的相关性.方法 40例乳腺癌患者接受以蒽环类为基础的NAC.用免疫组化法检测NAC前ER、PR、c-erbB2及p53的表达情况,c-erbB2表达为阳性及强阳性者进一步行荧光原位杂交(FISH)检测,以确定HER-2基因的扩增水平.NAC结束后进行疗效评估.结果 40例患者中,缓解30例(75%),无缓解10例(25%);HER-2基因无扩增及p53表达阴性均与高反应性相关(P均<0.05);化疗≥4个周期的患者疗效达完全缓解的比例显著高于＜4个周期者(P<0.05).结论 HER-2基因无扩增及p53表达阴性的患者可能对以蒽环类为基础的化疗方案敏感;适当增加化疗周期数可能增加完全缓解率.
|
| 关 键 词： | 乳腺肿瘤 新辅助化疗 受体 表皮生长因子 蛋白质p53 蒽环类 |
The efficacy of anthracycline-based neoadjuvant chemotherapy in patients with breast cancer |
| |
| WANG Xiao-lan,CHEN Bo,YAO Fan,LI Ji-guang,LIU Nan,QIU Xue-shan,LIU Cai-gang,JIN Feng.The efficacy of anthracycline-based neoadjuvant chemotherapy in patients with breast cancer[J].Shandong Medical Journal,2008,48(32):1-3. |
| |
| Authors: | WANG Xiao-lan CHEN Bo YAO Fan LI Ji-guang LIU Nan QIU Xue-shan LIU Cai-gang JIN Feng |
| |
| Institution: | WANG Xiao-lan,CHEN Bo,YAO Fan,LI Ji-guang,LIU Nan,QIU Xue-shan,LIU Cai-gang,JIN Feng(The First Affiliated Hospital of China Medical University,Shenyang 110001,P.R.China) |
| |
| Abstract: | Objective To evaluate the predictive value of estrogen receptor(ER),progesterone receptor(PR),human epidermal growth factor receptor(c-erbB2)-2 and p53 in anthracycline-based neoadjuvant chemotherapy(NAC).Methods 40 patients with breast carcinoma were treated with anthracycline-based NAC.ER,PR,c-erbB2 and p53 were detected by immunohistochemistry staining before NAC.Fluorescence in situ hybridization(FISH) was used to detect the HER-2 gene amplification in the cases expression of c-erbB2 protein were(+ +) o... |
| |
| Keywords: | breast neoplasms neoadjuvant chemotherapy receptor epidermal growth factor protein p53 anthracyclines |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
